Results 121 to 130 of about 160,408 (307)

The biological therapy of IBD with special regards to its problems

, 2015
Biological therapy is a relatively new form of treatments. Many different therapeutic approaches can be cathegorized as biologics and many new agents may be classified unto them.
Olajos, Dániel Péter
core  

Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection

BACKGROUND & AIMS: Clostridioides difficile is a toxin-secreting bacteria that is an urgent antimicrobial resistance threat, with approximately 25% of patients developing recurrent infections.
Wang, X, Mah, R, Lunken, GR, Steiner, TS, Wong, MQ, Bressler, B, Cook, L, Schick, A, Peters, H, Lisko, DJ, Rees, WD, Oliveira, L, Lau, T, Levings, MK   +13 more
core   +1 more source

Improved inflammatory bowel disease (IBD) outcomes after adoption of the Australian IBD Standards

, 2019
Background and Aim: Australia has one of the highest incidences of inflammatory bowel disease (IBD) in the world. It is a lifelong inflammatory condition that frequently presents in young adulthood, with significant impacts on morbidity and quality of ...
Begun, J, Hendy, P, Howlett, M, Mickenbecker, M, Halliday, C, Palmer, A, Harris, H, An, Y, Lee, A, Mortimore, M   +9 more
core   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas   +7 more
wiley   +1 more source

Antimicrobial studies of Ficus benghalensis and Ficus racemosa on pathogenic viral diseases [PDF]

Advanced Herbal Medicine, 2017
Background and aims: Medicinal plant products are considered to be an effective candidate against the number of viral diseases as generally observed or reported in developing countries. As per the literature, secondary metabolites (i.e.
Amit Gupta, Sushama Chaphalkar
doaj  

Long‐Term Risk of Rheumatoid Arthritis in Individuals With Autism Spectrum Disorder: A Population‐Based Matched Cohort Study

Autism Research, EarlyView.
ABSTRACT To investigate the long‐term risk of rheumatoid arthritis (RA) among individuals with autism spectrum disorder (ASD), addressing potential immune comorbidity in ASD populations. A population‐based matched cohort was assembled using Swedish registers, including 46,164 individuals diagnosed with ASD between 1987 and 2017, matched to 4,634,895 ...
Evora Hailin Zhu, Stephen Z. Levine, Matilda Morin, Weiyao Yin, Benjamin Christofferson, Johan Askling, Natalia Rivera, Abraham Reichenberg, Joseph D. Buxbaum, Sven Sandin, Benjamin Hon Kei Yip   +10 more
wiley   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

A machine learning framework reveals key drivers of cytokine responses in a healthy human cohort

npj Systems Biology and Applications
Population based studies are essential to evaluate the impact of the genetic and environmental determinants that influence the regulation of the human immune response.
Claire Liefferinckx, Jérémie Bottieau, Eric Quertinmont, Vjola Tafciu, Charlotte Minsart, Denis Franchimont   +5 more
doaj   +1 more source

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G. Johnson, Elena Peeva, Michael S. Vincent, Valerie M. Clerin   +11 more
wiley   +1 more source

What's the next best cytokine target in IBD?

, 2012
In the gut of patients with inflammatory bowel disease (IBD), immune and nonimmune cells produce large amounts of cytokines that drive the inflammatory process leading to the tissue damage. Cytokine blockers, such as anti-tumor necrosis factor alpha (TNF-
MacDonald, Thomas T, Biancheri, Paolo, Monteleone, Giovanni, Sarra, Massimiliano   +3 more
core   +1 more source